IntegraGen

Equities

ALINT

FR0010908723

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 13:17:56 04/07/2024 BST			5-day change	1st Jan Change
0.55 ^EUR	+1.85%		0.00%	-38.48%

05-01	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI

IntegraGen Announces Unaudited Revenue Results for the Year 2016

January 09, 2017 at 04:58 pm

IntegraGen announced unaudited revenue results for the year 2016. For the year, the company reported sales revenue of EUR 6,022 million compared to EUR 5,593 million a year ago. The growth in annual revenue for 2016 was 8% compared to full year 2015 results.

Latest news about IntegraGen

IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	05-01	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	23/10/23	CI
IntegraGen SA Announces Revenue Results for the First Half of 2023	13/07/23	CI
IntegraGen Announces Unaudited Revenue Results for the Full Year 2022	13/01/23	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2022	18/10/22	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	18/10/22	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	18/10/22	CI
IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2021	29/04/22	CI
IntegraGen SA Announces Earnings Result for the First Half of 2021	08/10/21	CI
Global markets live: Intel, Moderna, Burberry, Pfizer, SoftwareOne, Swisscom...	16/07/21
IntegraGen SA Announces Unaudited Turnover for the First Half of 2021	16/07/21	CI
Integragen Sa Reports Earnings Results for the Full Year Ended December 31, 2020	20/04/21	CI
OncoDNA SA completed the acquisition of 64.7% stake in IntegraGen SA for €9.4 million.	11/11/20	CI
Integragen Sa Reports Earnings Results for the Half Year Ended June 30, 2020	17/09/20	CI
IntegraGen Announces Unaudited Sales for the First Half of 2020	09/07/20	CI
OncoDNA SA signed an agreement to acquire IntegraGen SA for €14.5 million.	08/07/20	CI
U.S. Cancer Center to Use IntegraGen's MERCURY™ Cloud-Based Tool for Oncology Sequencing Data Interpretation and Reporting	26/03/20	CI
IntegraGen SA Announces Financial Results for the Half Year Ended June 30, 2018	19/09/18	CI
IntegraGen SA Announces Results of the Ability of miR-31-3p to Predict Response to Therapy for Patients with Metastatic Colorectal Cancer	04/09/18	CI
The SeqOIA Cooperative Health Group Selects Integragen as the Operator of its Sequencing Platform as Part of the France Genomic Medicine 2025 Plan	31/07/18	CI
IntegraGen SA Announces Earnings Results for the Year Ended Dec. 31, 2017; Provides Revenue Guidance for 2018	12/04/18	CI
IntegraGen Presents Positive Data from Liquid Biopsy Studies of Company’s Proprietary miRNAs during 2018 European Lung Cancer Conference	12/04/18	CI
IntegraGen SA Announces Global Distribution Agreement with Twist Bioscience Corp	14/02/18	CI
IntegraGen and GoPath Laboratories Sign Licensing Agreement for the Commercialization of Mir-31-3P Test in North America	09/01/18	CI
Integragen Sa Announces Results from an Analysis of miR-31-3p Expression in Tumor Samples from Patients Enrolled in the NEW EPOC Clinical Trial	09/10/17	CI

Chart IntegraGen

Duration

Period

More charts

Company Profile

IntegraGen specializes in researching and identifying genetic biomarkers and in developing and marketing molecular diagnostic products and services, primarily in the field of oncology. The group's activity is organized around two sectors: - supply of genomic research services: high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups; - sales of diagnostic solutions. France accounts for 84.7% of net sales.

Sector

Biotechnology & Medical Research

Calendar

16/10/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INTEGRAGEN	-38.48%	3.86M
EXACT SCIENCES CORPORATION	-41.62%	7.97B
GUARDANT HEALTH, INC.	+5.03%	3.48B
IOVANCE BIOTHERAPEUTICS, INC.	-9.10%	2.07B
BGI GENOMICS CO., LTD.	-29.56%	1.83B
VERACYTE, INC.	-21.96%	1.64B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+6.72%	928M
SEEGENE, INC.	-9.17%	690M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-30.82%	500M
CURIOX BIOSYSTEMS CO., LTD	-16.50%	248M

Bio Diagnostics & Testing